Abstract | BACKGROUND AND AIMS: METHODS: RESULTS: Of the study population (n = 78 762), 27 047 (34.3%) and 24 036 (30.5%) subjects had MAFLD and NAFLD respectively. A total of 1084 (4.0%) or 921 (3.8%) subjects had previous CVD history in MAFLD or NAFLD subgroup respectively. The previous CVD history and high probability of ASCVD were significantly higher in MAFLD or NAFLD subgroup with significant liver fibrosis than in the other groups (all p < .001). In multivariable analysis, MAFLD was independently associated with previous CVD history after adjusting for confounders (adjusted odds ratio [aOR] = 1.10, p = .038), whereas NAFLD was not (all p > .05). MAFLD (aOR = 1.40) or NAFLD (aOR = 1.22) was independently associated with high probability of ASCVD after full adjustment respectively (all p < .001). Significant liver fibrosis was independently associated with previous CVD history and high probability of ASCVD after adjustment in MAFLD or NAFLD subgroup respectively (all p < .05). CONCLUSION: MAFLD might better identify subjects with CVD risk than NAFLD. Fibrosis assessment might be helpful for detailed prognostication in subjects with MAFLD.
|
Authors | Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong-Ho Lee, Ji-Hye Kim, Seung Up Kim |
Journal | Liver international : official journal of the International Association for the Study of the Liver
(Liver Int)
Vol. 43
Issue 3
Pg. 608-625
(03 2023)
ISSN: 1478-3231 [Electronic] United States |
PMID | 36585250
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Aspartate Aminotransferases
|
Topics |
- Humans
- Non-alcoholic Fatty Liver Disease
- Risk Factors
- Cardiovascular Diseases
- Heart Disease Risk Factors
- Aspartate Aminotransferases
- Liver Cirrhosis
|